Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Campus
Campus

New 2022 ADA/EASD guidelines: GLPP-1 RA/Insulin combination is recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

Soliqua API

Reference

  1. American Diabetes Association. Diabetes Care 2023;46(Suppl. 1):S140–S157 | https://doi.org/10.2337/dc23-S009.
Related articles
MAT-BH-2300161/v1/March 2023